Avalanche Biotechnologies Header Image: Iris
Sustained Therapeutic delivery for the eye

Privacy Policy

Thank you for visiting the Avalanche Biotechnologies website and for reviewing our privacy policy. The following statement explains our policy regarding personal information you may supply when visiting our website: Avalanche Biotechnologies does not sell, rent, or share information with any other organization. We do not transfer information for any promotional or marketing purposes, nor is that information shared with any third parties whatsoever. Our website contains links to other sites. We are not responsible for the privacy practices of these websites.

Avalanche Biotechnologies to Present at the Ophthalmology Innovation Summit at the American Academy of Ophthalmology 2014 Annual Meeting

October 9, 2014

MENLO PARK, CA – October 9, 2014 – Avalanche Biotechnologies, Inc. (Nasdaq: AAVL), a clinical-stage biotechnology company focused on discovering and developing novel gene therapies to transform the lives of patients with sight-threatening ophthalmic diseases, today announced that Thomas W. Chalberg, Jr., Ph.D., Founder and Chief Executive Officer, will present at the Ophthalmology Innovation Summit at the American Academy of Ophthalmology 2014 Annual Meeting on Thursday, October 16, 2014 at 8:49 am CDT in Chicago, IL. Additionally, Dr. Chalberg will participate in the “IPOs in Ophthalmology – The Class of 2014 and Beyond” at 4:10 pm CDT.

Read More

Read All Avalanche News